Exchange: NASDAQ·Updated 07:30 PM EDT
ACOG logo

ACOG Alpha Cognition Inc

$8.78
$0.17
(1.90%)
Today
Closed $8.78
$0.00
(0.00%)
After Hours
EarningsNov 12
Mkt Cap$194.91M
Vol59,044.00

About ACOG

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. It has additional pre-clinical development programs: ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease, ALPHA-1062 sublingual formulation, ALPHA-1062 intranasal (“ALPHA-1062IN”) formulation for the treatment of cognitive impairment with mild traumatic brain injury (mTBI, otherwise known as concussion) and ALPHA-0602, ALPHA-0702 & ALPHA-0802. The company was founded in 2000 and is headquartered in Grapevine, TX.
52

Neutral Sentiment

How do you feel about ACOG?

Advertisement|Remove ads.